<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>igusabder</journal-id>
            <journal-title-group>
                                                                                    <journal-title>İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">2536-4499</issn>
                                        <issn pub-type="epub">2602-2605</issn>
                                                                                            <publisher>
                    <publisher-name>İstanbul Gelisim University</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id pub-id-type="doi">10.38079/igusabder.1628465</article-id>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Medical Physics</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Tıp Fiziği</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <trans-title-group xml:lang="tr">
                                    <trans-title>Mesane Kanseri İçin Tedavi Planlarının Karşılaştırılması: FIF, YART ve SIB: Dozimetrik Bir Çalışma</trans-title>
                                </trans-title-group>
                                                                                                                                                                                                <article-title>Comparing Treatment Plans for Bladder Cancer: FIF, IMRT and SIB: A Dosimetric Study</article-title>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0003-2995-0256</contrib-id>
                                                                <name>
                                    <surname>İnan</surname>
                                    <given-names>Gökçen</given-names>
                                </name>
                                                                    <aff>SELÇUK ÜNİVERSİTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-6773-3132</contrib-id>
                                                                <name>
                                    <surname>Gül</surname>
                                    <given-names>Osman Vefa</given-names>
                                </name>
                                                                    <aff>SELCUK UNIVERSITY</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                    <contrib-id contrib-id-type="orcid">
                                        https://orcid.org/0000-0002-2122-8720</contrib-id>
                                                                <name>
                                    <surname>Başaran</surname>
                                    <given-names>Hamit</given-names>
                                </name>
                                                                    <aff>SELCUK UNIVERSITY</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20260429">
                    <day>04</day>
                    <month>29</month>
                    <year>2026</year>
                </pub-date>
                                                    <issue>28</issue>
                                        <fpage>57</fpage>
                                        <lpage>68</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20250128">
                        <day>01</day>
                        <month>28</month>
                        <year>2025</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20260311">
                        <day>03</day>
                        <month>11</month>
                        <year>2026</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2017, Istanbul Gelisim University Journal of Health Sciences</copyright-statement>
                    <copyright-year>2017</copyright-year>
                    <copyright-holder>Istanbul Gelisim University Journal of Health Sciences</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="tr">
                            <p>Amaç: Bu çalışmanın amacı, alan içi alan (FIF), yoğunluk ayarlı radyoterapi (YART) ve eşzamanlı entegre boost (SIB) tekniği kullanılarak mesane kanseri için yapılan planları karşılaştırmaktır.Yöntem: Mesane kanseri tanısı almış 20 hastanın tomografi görüntüleri kullanılarak FIF, YART ve SIB tedavi planları oluşturuldu. Her hasta için iki ayrı planlama hedef hacmi (PTV) tanımlandı: PTV1 ve PTV2. FIF ve YART planları için, PTV1 ve PTV2&#039;ye sırasıyla 33 fraksiyonda 50,4 Gray (Gy) ve 60 Gy tedavi dozları verildi. 28 günlük fraksiyonda hedef hacimlerde farklı dozların eş zamanlı olarak verildiği SIB yöntemi kullanıldı. SIB tekniğinde günlük tedavi dozu 2,14 Gy olarak belirlendi. Planlar PTV, rektum, bağırsak, femur başları gibi kritik organlar, homojenlik indeksi (HI), konformite indeksi (HI) ve monitör unit değerleri (MU) açısından karşılaştırıldı.Bulgular: Tüm planlar, hedef hacimdeki dozun %95&#039;ini kapsayacak şekilde tasarlandı. SIB planlarının CI’si FIF ve YART planlarına kıyasla anlamlı derecede daha iyi sonuçlar gösterdi. SIB planlarında rektum için V45 ve V30 dozları, FIF planlarına kıyasla istatistiksel olarak anlamlı derecede daha düşüktü (p&amp;lt;0,05). Rektum V30 BED değerleri, SIB planlarında 57,01±11,94 ve YART planlarında 56,37±10,95 olarak bulundu. MU sayıları, FIF planlarında anlamlı derecede düşüktü (p&amp;lt;0,05).Sonuç: SIB tekniği, mesane radyoterapisinde FIF ve YART tekniklerine kıyasla kritik organları daha iyi korumuştur. Ancak BED analizi, SIB ile daha yüksek dozlara işaret etmektedir. Genel olarak, kritik organlara verilen dozun dikkatlice izlenmesi koşuluyla, SIB uygun hastalar için uygulanabilir bir seçenek gibi görünmektedir.</p></trans-abstract>
                                                                                                                                    <abstract><p>Aim: The purpose of this study is to compare plans for bladder cancer using field-in-field (FIF), intensity modulated radiotherapy (IMRT) and simultaneous integrated boost (SIB) technique.Method: FIF, IMRT and SIB treatment plans were created using tomography images of 20 patients diagnosed with bladder cancer. Two separate planning target volume (PTV) were defined for each patient: PTV1 and PTV2. For the FIF and IMRT plans, PTV1 and PTV2 received treatment doses of 50.4 Gray (Gy) and 60 Gy in 33 fractions, respectively. In 28 daily fractions, the SIB method was used in which different doses were delivered simultaneously in the target volumes. In the SIB technique, the daily treatment dose was determined as 2.14 Gy. The plans were compared in terms of PTV, organs at risk (OARs) such as rectum, bowel, femoral heads, homogeneity index (HI), conformity index (CI) and monitor unit values (MU).Results: All plans were designed to cover 95% of the dose in the target volume. The CI for SIB plans showed significantly favourable results compared to FIF and IMRT plans. The V45 and V30 doses for the rectum in the SIB plans were statistically significantly lower compared to the FIF (p&amp;lt;0.05). The biologically effective doses (BED) values of rectum V30 were found to be 57.01±11.94 in SIB plans and 56.37±10.95 in IMRT plans. MU counts were significantly lower in FIF plans (p&amp;lt;0.05).Conclusion: The SIB technique demonstrated better sparing of critical organs compared with FIF and IMRT in bladder radiotherapy. BED analysis, however, indicated higher doses with SIB. Overall, SIB appears to be a feasible option for appropriate patients, provided that dose to critical organs is carefully monitored.</p></abstract>
                                                            
            
                                                                                        <kwd-group>
                                                    <kwd>Bladder cancer</kwd>
                                                    <kwd>  radiotherapy</kwd>
                                                    <kwd>  simultaneous integrated boost</kwd>
                                            </kwd-group>
                            
                                                <kwd-group xml:lang="tr">
                                                    <kwd>Mesane kanseri</kwd>
                                                    <kwd>  radyoterapi</kwd>
                                                    <kwd>  eş zamanlı integral boost</kwd>
                                            </kwd-group>
                                                                                                                                        </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">1.	Jemal A, Bray F, Center MM, Ferlay C, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">2.	Martin-Doyle W, Kwiatkowski DJ. Molecular biology of bladder cancer. Hematol. Oncol Clin North Am. 2015;29:191–203. doi: 10.1016/j.hoc.2014.10.002.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">3.	Lee ST, Lawrentschuk N, Scott AM. PET on prostate and bladder tumors. Semin Nucl Med. 2012;42:231-46.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">4.	Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009;55(4):815-25.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">5.	Chavan S, Bray F, Lortet-Tieulent J, Goodman M, Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol. 2014;66(1):59–73.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">6.	Edward CH, Carlos AP, Luther WB. Perez and Brady’s Principles and Practice of Radiation Oncology. Lippincott Williams&amp;Wilkins (ed.), 5. New York, USA. 2007</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">7.	Agulnik M. Puataweepong P. Advanced Radiation Therapy for Head and Neck Cancer: A New Standard of Practise. 1st Edition. Thailand Intech Press. 2012;232-235.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">8.	Chao S, Apisarnthanarax S, Ozyigit G. Practical Essentials of Intensity Modulated Radiation Therapy. Lippincott Williams &amp; Wilkins. 2005.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">9.	Sondergaard J, Hoyer M, Petersen JB, Wright P, Grau C, Muren LP. The normal tissue sparing obtained with simultaneous treatment of pelvik lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncologica. 2009;48(2):238-44.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">10.	Wu Q, Mohan R, Morris M, Lauve A, Schmidt-Ullrich, R. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head and neck squamous cell carcinomas: I:dosimetric results. International Journal of Radiation Oncology Biology Physics. 2003;60(2):374-387. doi: 10.1016/s0360-3016(02)04617-5.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">11.	Mohan R, Wu Q, Manning M, Schmidt-Ulrich R. Radiobiological considerations in teh design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. International Journal of Radiation Oncology Biology Physics. 2000;46(3):619-630. doi: 10.1016/s0360-3016(99)00438-1.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">12.	Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi, P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) in intensity modulated radiotherapy (IMRT) for head and neck cancer. Critical Reviews in Oncology Hematol. 2010;73(2):111-125. doi: 10.1016/j.critrevonc.2009.03.003.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">13.	Hodapp N. ICRU Report 83: Prescribing, recording, and Reporting photon beam Intensity Modulated Radiation Therapy(IMRT). Strahlenther Onkol. 2012;188(1):97-9.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">14.	Jones D. ICRU Report 50: Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements. Medical Physics. 1993.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">15.	Jones B, Dale RG, Finst P, Khaksar SJ. Biological equivalent dose assessment of the consequences of hypofractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2000;47:1379–1384.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">16.	Melvin A. Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med. Phys. 2008;35:4161–4172.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">17.	Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans: Technical note. J Neurosurg. 2000;93(suppl 3):219-222.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">18.	Milosevic M, Gospodarowicz M, Jewett M, Bristow R, Haycocks T. Intensity-Modulated Radiation Therapy for lymph node metastases in bladder cancer; In Clinical Target Volumes In Conformal And Intensity Modulated Radiation Therapy. 2004:157-169.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">19.	Çelen YY, Kızılkaya HO. Difference of Simultaneous Integrated Boost Technique after Breast Conserving Surgery. European Journal of Science and Technology. 2020;19:578-87. doi: 10.31590/ejosat.719046</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">20.	Nageeti T, Mahfouz M, Abdallah H, Algaoud M, Zatar R. Dosimetric comparison of simultaneous ıntegrated vs. sequential boost in radiotherapy for high grade gliomas. Cancer Ther Oncol Int J. 2019;15:68-71. doi: 10.19080/CTOIJ.2019.15.555907</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">21.	Feng CH, Hasan Y, Kopec M. Hallaq H. Simultaneously integrated boost (SIB) spares OAR and reduces treatment time in locally advanced cervical cancer. Journal of Appl. Clin. Med. Phy. 2016;17(5):6123.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">22.	Li L, Xin Y, Cui H, Zhao X, Dang J, Li Y. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced drug-resistant gastrointestinal stromal tumors: a feasibility study. Front. Oncol. 2020;10.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">23.	Moamen A, Abo-Madyan Y, Jahnke L, Wenz F, Glatting G. Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram. Radiation Oncology. 2016:11-16. doi: 10.1186/s13014-016-0590-1.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">24.	Bakkal BH, Elmas O. Dosimetric comparison of organs at risk in 5 different radiotherapy plans in patients with preoperatively irradiated rectal cancer. Medicine (Baltimore). 2021;100(1):e24266. doi: 10.1097/MD.0000000000024266</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
